Everolimus Added to Fulvestrant Upped PFS in Postmenopausal HR+ Breast Cancer Patients
Posted: Friday, March 17, 2017
Investigators seeking to extend the chemotherapy-free period for women with metastatic hormone receptor–positive, HER2-negative breast cancer continue to explore attractive treatment options for this tumor subtype. Everolimus plus exemestane is an approved regimen for patients whose disease progresses on first-line endocrine therapy alone, and the more recent approval of the CDK 4/6 inhibitor palbociclib plus letrozole or fulvestrant also can postpone the necessity for chemotherapy. Now, a report from the 2016 San Antonio Breast Cancer Symposium suggests that the combination of everolimus and fulvestrant may also be useful as second-line treatment, which again delays the switch to chemotherapy in these patients with metastatic disease.